Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial

Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial

Rituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for refractory nephrotic syndrome (NS) on the basis of favorable clinical observations. While reported efficacy of RTX on refractory RTX is promising, the long-term effect obtained from randomized clinical trial is...

Full description

Bibliographic Details
Main Authors: Yo Han Ahn, Hee Gyung Kang, Seong Heon Kim, Kyoung Hee Han, Hee Yeon Cho, Jae Il Shin, Min Hyun Cho, Young Seo Park, Su Yung Kim, Seung Joo Lee, Hae Il Cheong, Il-Soo Ha
Format: Article
Language:English
Published: The Korean Society of Nephrology 2014-06-01
Series:Kidney Research and Clinical Practice
Online Access:http://www.sciencedirect.com/science/article/pii/S2211913214000485

Internet

http://www.sciencedirect.com/science/article/pii/S2211913214000485

Similar Items